Cyprotex chief confident of future prospects

DRUG testing company Cyprotex has said that it expects its 2011 sales to be 30% ahead of the prior year, in line with management expectations.

The firm also said that it remains cash-positive despite "significant" investment in new technologies, and would finish the year with around £1.1m of cash, compared with £1.04m at the start.

The company said that it had experienced a strong period of trading in the second half of the year in both its ADME and toxicity businesses.

"We have added several n... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...